Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 177)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
2 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
Buccolam
Buccolam®|Dormicum®|Nayzilam®|USL261 (nasal spray formulation)|Versed®
Dea no. 2884
Dormicum
Hydrochloride, midazolam
Maleate, midazolam
Mezolam
Midazolam
Midazolam base
MIDAZOLAM CIV
|
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Nayzilam
USL261
USL-261
Versed
|
|
3 |
|
Propofol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
2078-54-8 |
4943 |
Synonyms:
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Diisopropylphenol
2,6-diisopropylphenol|Diprivan®|ICI 35868
Abbott brand OF propofol
Alpha Brand OF propofol
Aquafol
Astra brand OF propofol
AstraZeneca brand OF propofol
Braun brand OF propofol
Curamed brand OF propofol
Diisopropylphenol
Diprivan
Disoprivan
Disoprofol
Fresenius brand OF propofol
Fresenius kabi brand OF propofol
Fresofol
ICI 35868
ICI 35-868
|
ICI35,868
ICI-35868
Ivofol
Juste brand OF propofol
NSC-5105
Parnell brand OF propofol
Pisa brand OF propofol
Propofol
Propofol abbott
Propofol fresenius
Propofol MCT
Propofol rovi
Propofol-lipuro
Propofolum
Rapinovet
Recofol
Rovi brand OF propofol
Schering brand OF propofol
Zeneca brand OF propofol
|
|
4 |
|
Rifaximin |
Approved, Investigational |
Phase 4 |
|
80621-81-4 |
46783403 6436173 |
Synonyms:
(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-2,15,17,23,36-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6-oxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1,.0,.0,.0,]heptatriaconta-1(35),2,4,9,19,21,23,25(36),26(34),28,30,32-dodecaen-13-yl acetic acid
4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin
NORMIX
Redactiv
RIFACOL
RIFAMYCIN L 105
RIFAMYCIN L 105SV
RIFAXIDIN
Rifaximin
|
RIFAXIMINA
RIFAXIMINE
RIFAXIMINUM
RIFAXIMINUN
TARGAXAN
Xifaxan
XIFAXANTA
XIFAXSAN
|
|
5 |
|
Lactulose |
Approved |
Phase 4 |
|
4618-18-2 |
11333 |
Synonyms:
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5R)-4,5-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)OXOLAN-3-YL]OXY-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL]OXY-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-DIMETHYLOL-TETRAHYDROFURAN-3-YL]OXY-6-METHYLOL-TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-[[(2R,3S,4S,5S)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)-3-TETRAHYDROFURANYL]OXY]-6-(HYDROXYMETHYL)TETRAHYDROPYRAN-3,4,5-TRIOL
(2S,3R,4S,5R,6R)-2-{[(2R,3S,4S,5R)-4,5-DIHYDROXY-2,5-BIS(HYDROXYMETHYL)OXOLAN-3-YL]OXY}-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL
4-O-b-D-Galactopyranosyl-D-fructofuranose
4-O-b-D-Galactopyranosyl-D-fructose
4-O-beta-delta-Galactopyranosyl-delta-fructofuranose
4-O-beta-delta-Galactopyranosyl-delta-fructose
4-O-beta-D-Galactopyranosyl-D-fructofuranose
4-O-beta-D-Galactopyranosyl-D-fructose
4-O-Β-D-galactopyranosyl-D-fructofuranose
4-O-Β-D-galactopyranosyl-D-fructose
ACILAC
Amivalex
Bifiteral
Cephulac
CEPHULAC SYRUP
CHOLAC
Chronulac
CONSTILAC
|
CONSTULOSE
delta-Lactulose
D-Lactulose
Duphalac
DUPHALAC DRY
E966
ENULOSE
EVALOSE
GENERLAC
HEPTALAC
Lactulosa
Lactulose
LACTULOSE JP17
Lactulosum
LAXILOSE
LAXOSE ORANGE
LEMLAX
Normase
OSMOLAX
PORTALAC
REGULOSE
|
|
6 |
|
Midodrine |
Approved |
Phase 4 |
|
133163-28-7, 42794-76-3 |
4195 |
Synonyms:
(+-)-2-Amino-N-(beta-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(b-hydroxy-2,5-dimethoxyphenethyl)acetamide
(+-)-2-Amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
(±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide
1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol
2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-b-hydroxyphenethyl)acetamide
2-Amino-N-(2,5-dimethoxy-β-hydroxyphenethyl)acetamide
A-4020 LINZ
Amatine
Cahill may roberts brand OF midodrine monohydrochloride
Christiaens brand OF midodrine monohydrochloride
DL-N1-(beta-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(b-Hydroxy-2,5-dimethoxyphenethyl)glycinamid
DL-N1-(Β-hydroxy-2,5-dimethoxyphenethyl)glycinamid
|
Gutron
Midodrin
Midodrina
Midodrine
Midodrine HCL
Midodrine hydrochloride
Midodrine monohydrochloride
Midodrinum
Midon
Monohydrochloride, midodrine
Nycomed brand OF midodrine monohydrochloride
ProAmatine
Shire brand OF midodrine monohydrochloride
ST 1085
ST-1085
|
|
7 |
|
Buprenorphine |
Approved, Illicit, Investigational, Vet_approved |
Phase 4 |
|
52485-79-7, 53152-21-9 |
644073 40400 |
Synonyms:
(−)-buprenorphine
(-)-Buprenorphine
17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol
2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol
2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol
2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol
21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
ALKS-5461 COMPONENT BUPRENORPHINE
BUPEAZE
BUPLAST
Buprel
Buprenex
Buprenex®|Buvidal®|CAM2038|Sixmo® (buprenorphine hydrochloride)|Subutex®|Temgesic®
Buprenophine
Buprenorfina
Buprenorfina [INN-Spanish]
BUPRENORPHINE
Buprenorphine grünenthal brand
Buprenorphine Hcl
Buprenorphine hydrochloride
Buprenorphinum
Buprenorphinum [INN-Latin]
Buprex
|
BUTEC
BUTRANS
Essex brand OF buprenorphine hydrochloride
Grünenthal brand OF buprenorphine
Grünenthal brand OF buprenorphine hydrochloride
HAPOCTASIN
Hydrochloride, buprenorphine
Key brand OF buprenorphine hydrochloride
PANITAZ
Prefin
PRENOTRIX
Probuphine
Reckitt and colman brand 1 OF buprenorphine hydrochloride
Reckitt and colman brand 2 OF buprenorphine hydrochloride
Reckitt benckiser brand OF buprenorphine hydrochloride
Reckitt brand OF buprenorphine hydrochloride
RELETRANS
RX 6029 m
RX-6029-m
Schering plough brand OF buprenorphine hydrochloride
Schering-plough brand OF buprenorphine hydrochloride
SEVODYNE
SUBLOCADE
Subutex
Temgesic
Temgésic
TEPHINE
TRANSTEC
|
|
8 |
|
Naloxone |
Approved, Vet_approved |
Phase 4 |
|
465-65-6 |
5284596 |
Synonyms:
(-)-Naloxone
(−)-NALOXONE
(-)-naloxone|Kloxxado® (naloxone hydrochloride nasal spray)|l-naloxone|Narcan®|Nyxoid®
[<i>N</i>-allyl-2,3-<sup>3</sup>H]naloxone
17-Allyl-3,14-dihydroxy-4,5a-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one
17-Allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
1-N-Allyl-14-hydroxynordihydromorphinone
Abello brand OF naloxone hydrochloride
Abello, naloxone
Boots brand OF naloxone hydrochloride
Bristol myers squibb brand OF naloxone hydrochloride
Bristol-myers squibb brand OF naloxone hydrochloride
Curamed brand OF naloxone hydrochloride
Curamed, naloxon
DBL Naloxone
Dihydride, naloxone hydrochloride
EN 1530 base
endo Brand OF naloxone hydrochloride
Hydrobromide, naloxone
Hydrochloride dihydride, naloxone
Hydrochloride, naloxone
Lamepro brand OF naloxone hydrochloride
L-Naloxone
MRZ 2593 BR
MRZ 2593BR
MRZ 2593-BR
N-Allylnoroxymorphone
|
Nalone
Nalossone
Nalossone [Dcit]
Naloxon curamed
Naloxon ratiopharm
Naloxona
Naloxona [INN-Spanish]
NALOXONE
Naloxone abello
Naloxone HCl
Naloxone hydrobromide
Naloxone hydrochloride
Naloxone hydrochloride dihydride
Naloxone hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-isomer
Naloxonratiopharm
Naloxon-ratiopharm
Naloxonum
Naloxonum [INN-Latin]
Narcan
Narcanti
Narcon
NSC-70413
Ratiopharm brand OF naloxone hydrochloride
SERB brand OF naloxone hydrochloride
SUBOXONE
United drug brand OF naloxone hydrochloride
|
|
9 |
|
Carvedilol |
Approved, Investigational |
Phase 4 |
|
72956-09-3 |
2585 |
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
14C-Labeled carvedilol
Artist
BM 14.190
BM-14.190
BM-14190
BM-14-190
C07AG02
CARVEDILOL
Carvédilol
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
Carvedilol, (R)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
|
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
Coreg
COREG CR
Coreg®|DQ 2466|Eucardic®|SKF 105517
Coropres
Dilatrend
DQ 2466
DQ-2466
Eucardic
EUCARDIC 12.5
EUCARDIC 25
EUCARDIC 3.125
EUCARDIC 6.25
Kredex
Querto
SKF 105517
SKF-105517
|
|
10 |
|
Propranolol |
Approved, Investigational |
Phase 4 |
|
318-98-9, 525-66-6 |
62882 4946 |
Synonyms:
(+-)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-NAPHTHYLOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPANE HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHOXY)-PROPAN-2-OL HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-ISOPROPYLAMINO-3-(1-NAPHTHOXY)-PROPAN-2-OL-HYDROCHLORIDE
Anaprilin
Anapriline
ANGILOL
APSOLOL
Avlocardyl
AY-64043
AY-64043-
BEDRANOL
BEDRANOL S.R.
Bedranol®|Hemangiol®|Inderal®|propranolol hydrochloride
Beprane
BERKOLOL
Betachron
Betadren
BETADUR CR
Betalong
Beta-Neg
BETA-PROGRANE MR
beta-Propranolol
Beta-Tablinen
Beta-Timelets
b-Propranolol
CARDINOL
Caridolol
Corpendol
Deralin
Dexpropranolol
Dl-Propranolol Hydrochloride
Dociton
DUPROMEX
Duranol
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HALF BETA-PROGRANE MR
HALF PROPANIX LA
HALF PROPATARD LA
HALF-BEPRANE CR
HALF-BETADUR CR
HALF-INDERAL LA
HEMANGEOL
Hydrochloride, propranolol
ICI-45520
Inderal
INDERAL LA
|
Inderide
INDERIDE-40/25
INDERIDE-80/25
Indobloc
INNOPRAN
INNOPRAN XL
Intermigran
Kemi S
LEDERPRONOL
LOPRANOL LA
Migrastat
NSC-91523
Obsidan
Obzidan
Oposim
Prano-Puren
PROBETA LA
Propanalol
Propanix
PROPANIX LA
PROPANIX-10
PROPANIX-160
PROPANIX-160 SR
PROPANIX-40
PROPANIX-80
Propanolol
PROPATARD LA
Prophylux
Propranalol
PROPRANOLOL
PROPRANOLOL HCL
Propranolol Hcl Intensol
Propranolol hydrochloride
PROPRANOLOL HYDROCHLORIDE INTENSOL
Propranololo
Propranololum
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
RAPRANOL SR
Rapynogen
Reducor
Reducor Line
Rexigen
SAGITTOL
Servanolol
SLO-BLOK
SLO-PRO
SLOPROLOL
Sumial
SYPROL
TESNOL
Β-propranolol
|
|
11 |
|
Insulin aspart |
Approved |
Phase 4 |
|
116094-23-6 |
16132418 |
Synonyms:
ASPART
ASPART INSULIN
B28-ASPART-INSULIN
B28-ASP-INSULIN
FIASP
FIASP FLEXTOUCH
FIASP PENFILL
INA-X14
INS NOVORAPID
INSULIN ASPART
Insulin aspart protamine
Insulin aspart protamine recombinant
INSULIN ASPART RECOMBINANT
|
INSULIN X14
INSULIN, ASP(B28)
Insulin, aspart protamine, human
Insulin, aspart, human
Insulin,aspart protamine
Insulina asparta
NOVOLOG
NOVOLOG FLEXPEN
NOVOLOG FLEXTOUCH
NOVOLOG INNOLET
NOVOLOG PENFILL
NOVORAPID
|
|
12 |
|
Valine |
Approved, Nutraceutical |
Phase 4 |
|
72-18-4 |
1182 6287 |
Synonyms:
(2S)-2-Amino-3-methylbutanoate
(2S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methylbutanoate
(S)-2-Amino-3-methyl-butanoate
(S)-2-Amino-3-methylbutanoic acid
(S)-2-Amino-3-methyl-butanoic acid
(S)-2-Amino-3-methylbutyrate
(S)-2-Amino-3-methylbutyric acid
(S)-a-Amino-b-methylbutyrate
(S)-a-Amino-b-methylbutyric acid
(S)-alpha-Amino-beta-methylbutyrate
(S)-alpha-Amino-beta-methylbutyric acid
(S)-Valine
2-Amino-3-methylbutanoate
2-Amino-3-methylbutanoic acid
2-Amino-3-methylbutyrate
2-Amino-3-methylbutyric acid
DL-Valine
Hval
L Valine
L-(+)-a-Aminoisovalerate
L-(+)-a-Aminoisovaleric acid
|
L-(+)-alpha-Aminoisovalerate
L-(+)-alpha-Aminoisovaleric acid
L-(+)-Α-aminoisovalerate
L-(+)-Α-aminoisovaleric acid
L-a-Amino-b-methylbutyrate
L-a-Amino-b-methylbutyric acid
L-alpha-Amino-beta-methylbutyrate
L-alpha-Amino-beta-methylbutyric acid
L-VAL
L-Valin
L-VALINE
L-Α-amino-β-methylbutyrate
L-Α-amino-β-methylbutyric acid
NSC-76038
Poly(L-val)
Polyvaline
V
Val
Valin
Valina
VALINE
|
|
13 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
14 |
|
Aspartic acid |
Approved, Nutraceutical |
Phase 4 |
|
56-84-8 |
5960 |
Synonyms:
(+)-Aspartate
(+)-Aspartic acid
(+-)-Aspartic acid
(2S)-2-AMINOBUTANEDIOIC ACID
(2S)-2-AMINOSUCCINIC ACID
(2S)-Aspartate
(2S)-Aspartic acid
(L)-Aspartate
(L)-Aspartic acid
(R)-2-Aminosuccinate
(R,S)-Aspartic acid
(S)-(+)-Aspartate
(S)-(+)-Aspartic acid
(S)-2-Aminobutanedioate
(S)-2-Aminobutanedioic acid
(S)-2-Aminosuccinate
(S)-2-Aminosuccinic acid
(S)-Aminobutanedioate
(S)-Amino-butanedioate
(S)-Aminobutanedioic acid
(S)-Amino-butanedioic acid
(S)-Aspartate
(S)-Aspartic acid
[<sup>3</sup>H]-L-aspartate|[<sup>3</sup>H]-L-aspartic acid
2-Amino-3-methylsuccinate
2-Amino-3-methylsuccinic acid
2-Aminosuccinate
2-Aminosuccinic acid
ácido aspártico
Acidum asparticum
alpha-Aminosuccinate
alpha-Aminosuccinic acid
Aminosuccinate
Ammonium aspartate
Asp
Asparagate
Asparagic acid
Asparaginate
Asparaginic acid
Asparatate
ASPARTate
Aspartate magnesium hydrochloride
Aspartate, ammonium
Aspartate, calcium
Aspartate, dipotassium
Aspartate, disodium
Aspartate, magnesium
Aspartate, monopotassium
Aspartate, monosodium
Aspartate, potassium
Aspartate, sodium
|
ASPARTIC ACID
Aspartic acid, ammonium salt
Aspartic acid, calcium salt
Aspartic acid, dipotassium salt
Aspartic acid, disodium salt
Aspartic acid, hydrobromide
Aspartic acid, hydrochloride
Aspartic acid, magnesium (1:1) salt, hydrochloride, trihydrate
Aspartic acid, magnesium (2:1) salt
Aspartic acid, magnesium-potassium (2:1:2) salt
Aspartic acid, monopotassium salt
Aspartic acid, monosodium salt
Aspartic acid, potassium salt
Aspartic acid, sodium salt
Calcium aspartate
D
Dipotassium aspartate
Disodium aspartate
FEMA NO. 3656
H-Asp-OH
Hydrobromide aspartic acid
Hydrochloride aspartic acid
Hydrochloride, aspartate magnesium
L Aspartate
L Aspartic acid
L-(+)-Aspartate
L-(+)-Aspartic acid
L-Aminosuccinate
L-Aminosuccinic acid
L-Asp
L-Asp|L-aspartate
L-Asparagate
L-Asparagic acid
L-Asparaginate
L-Asparaginic acid
L-Asparaginsaeure
L-Asparaginsäure
L-Aspartate
L-Aspartic acid
Magnesiocard
Magnesium aspartate
MG 5 Longoral
MG5Longoral
MG-5-Longoral
Monopotassium aspartate
Monosodium aspartate
NSC-3973
Poly-DL-succinimide
Polysuccinimide
Potassium aspartate
Sodium aspartate
|
|
15 |
|
Ornithine |
Approved, Nutraceutical |
Phase 4 |
|
3184-13-2, 70-26-8 |
6262 |
Synonyms:
(+)-S-ORNITHINE
(2S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-DIAMINOPENTANOATE
(S)-2,5-DIAMINOPENTANOIC ACID
(S)-2,5-Diaminovalerate
(S)-2,5-DIAMINOVALERIC ACID
(S)-A,D-DIAMINOVALERATE
(S)-A,D-DIAMINOVALERIC ACID
(S)-a,delta-Diaminovalerate
(S)-a,delta-Diaminovaleric acid
(S)-a,Δ-diaminovalerate
(S)-a,Δ-diaminovaleric acid
(S)-alpha,delta-Diaminovalerate
(S)-ALPHA,DELTA-DIAMINOVALERIC ACID
(S)-ORNITHINE
(S)-Α,δ-diaminovalerate
(S)-Α,Δ-DIAMINOVALERIC ACID
2,5 Diaminopentanoic acid
2,5-Diaminopentanoic acid
5-AMINO-L-NORVALINE
|
L-(-)-ORNITHINE
levo-ornithine
L-Ornithine
ORNITHINE
Ornithine dihydrochloride, (L)-isomer
Ornithine hydrochloride, (D)-isomer
Ornithine hydrochloride, (DL)-isomer
Ornithine hydrochloride, (L)-isomer
Ornithine monoacetate, (L)-isomer
Ornithine monohydrobromide, (L)-isomer
Ornithine monohydrochloride, (D)-isomer
Ornithine monohydrochloride, (DL)-isomer
Ornithine phosphate (1:1), (L)-isomer
Ornithine sulfate (1:1), (L)-isomer
Ornithine, (D)-isomer
Ornithine, (DL)-isomer
Ornithine, (L)-isomer
Ornithinum
Ornitina
|
|
16 |
|
GABA Modulators |
|
Phase 4 |
|
|
|
17 |
|
Anesthetics |
|
Phase 4 |
|
|
|
18 |
|
Hypnotics and Sedatives |
|
Phase 4 |
|
|
|
19 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
20 |
|
Anti-Anxiety Agents |
|
Phase 4 |
|
|
|
21 |
|
Psychotropic Drugs |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
23 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
24 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
25 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
26 |
|
Gastrointestinal Agents |
|
Phase 4 |
|
|
|
27 |
|
Adrenergic alpha-Agonists |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
29 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
30 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
31 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
32 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
33 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
34 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
35 |
|
Antioxidants |
|
Phase 4 |
|
|
|
36 |
|
Protective Agents |
|
Phase 4 |
|
|
|
37 |
|
Analgesics |
|
Phase 4 |
|
|
|
38 |
|
Buprenorphine, Naloxone Drug Combination |
|
Phase 4 |
|
|
|
39 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
40 |
|
Narcotic Antagonists |
|
Phase 4 |
|
|
|
41 |
|
Retinol palmitate |
|
Phase 4 |
|
|
|
42 |
|
Narcotics |
|
Phase 4 |
|
|
|
43 |
|
Hormones |
|
Phase 4 |
|
|
|
44 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
45 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
46 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
47 |
|
Adrenergic alpha-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
48 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
49 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
50 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 172)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy |
Unknown status |
NCT03100513 |
Phase 4 |
Lactulose;Polyethylene Glycol |
2 |
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy |
Unknown status |
NCT02401490 |
Phase 4 |
Human albumin;Placebo |
3 |
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study |
Unknown status |
NCT00896831 |
Phase 4 |
L-ornithine-L-aspartate;placebo |
4 |
Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis |
Unknown status |
NCT02470546 |
Phase 4 |
Metformin;Placebo |
5 |
Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study |
Unknown status |
NCT03987893 |
Phase 4 |
PEG-3350 with Electolytes;Lactulose |
6 |
Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics |
Unknown status |
NCT01356121 |
Phase 4 |
Propofol;Midazolam |
7 |
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy |
Unknown status |
NCT01178372 |
Phase 4 |
Lactulose;Probiotics(VSL#3) |
8 |
Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose |
Unknown status |
NCT01175538 |
Phase 4 |
Lactulose |
9 |
LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial |
Completed |
NCT01847651 |
Phase 4 |
LOLA or placebo |
10 |
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life |
Completed |
NCT00375375 |
Phase 4 |
Lactulose |
11 |
Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation |
Completed |
NCT00839358 |
Phase 4 |
albumin;Midodrine;Placebo |
12 |
Efficacy of Combined Oral L-ornithine-L-aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy |
Completed |
NCT00740142 |
Phase 4 |
L-ornithine-L-aspartate and lactulose;placebo and lactulose |
13 |
Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers |
Completed |
NCT01846455 |
Phase 4 |
2.0mg Buprenorphine/0.5mg Naloxone;Promethazine |
14 |
A Multicenter, Randomized, Open-Label, Active-Controlled, Trial to Evaluate the Safety and Efficacy of Rifaximin 550 mg With and Without Lactulose in Subjects With a History of Recurrent Overt Hepatic Encephalopathy |
Completed |
NCT01842581 |
Phase 4 |
Rifaximin;Lactulose |
15 |
Rifaximin and Its Microbial Resistance as a Secondary Prophylaxis of Hepatic Encephalopathy in Patients With HCV Related Cirrhosis |
Completed |
NCT04736836 |
Phase 4 |
Rifaximin |
16 |
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy |
Completed |
NCT02019784 |
Phase 4 |
Rifaximin-α;Placebo Oral Tablet |
17 |
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study |
Completed |
NCT03077217 |
Phase 4 |
Rifaximin |
18 |
Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension |
Completed |
NCT01059396 |
Phase 4 |
propranolol;carvedilol;placebo |
19 |
The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. |
Completed |
NCT01041755 |
Phase 4 |
L-ornithine-L-aspartate;Lactose |
20 |
Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study |
Completed |
NCT00955500 |
Phase 4 |
|
21 |
Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. |
Completed |
NCT00886925 |
Phase 4 |
Albumin;Sodium chloride 0.9% |
22 |
Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial |
Completed |
NCT01722578 |
Phase 4 |
L-ornithine L-aspartate;Placebo |
23 |
Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt |
Completed |
NCT01559519 |
Phase 4 |
Albumin |
24 |
Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients |
Completed |
NCT02158182 |
Phase 4 |
Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo |
25 |
Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy: a Randomized Controlled Trial |
Recruiting |
NCT05539027 |
Phase 4 |
Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA);Branched-chain amino acids (BCAA), enriched solution (Aminoleban) |
26 |
Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. |
Recruiting |
NCT04073290 |
Phase 4 |
Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution |
27 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy |
Recruiting |
NCT01846663 |
Phase 4 |
Placebo;Rifaximin |
28 |
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial) |
Recruiting |
NCT04436601 |
Phase 4 |
Polyethylene Glycols;Lactulose |
29 |
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. |
Terminated |
NCT01842113 |
Phase 4 |
Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo |
30 |
Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage |
Unknown status |
NCT00553423 |
Phase 3 |
Lactulose;Placebo |
31 |
A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy |
Unknown status |
NCT02464124 |
Phase 2, Phase 3 |
Nitazoxanide;Lactulose |
32 |
Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. |
Unknown status |
NCT01798329 |
Phase 3 |
|
33 |
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy |
Completed |
NCT00686920 |
Phase 3 |
Rifaximin |
34 |
Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study |
Completed |
NCT00433368 |
Phase 3 |
L-Ornithine L-Aspartate |
35 |
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life |
Completed |
NCT01008293 |
Phase 2, Phase 3 |
VSL#3;Lactulose |
36 |
A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen. |
Completed |
NCT00248625 |
Phase 3 |
N-acetylcysteine;Placebo |
37 |
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy |
Completed |
NCT00298038 |
Phase 3 |
Rifaximin;Placebo |
38 |
Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation |
Completed |
NCT01110447 |
Phase 2, Phase 3 |
VSL#3 |
39 |
Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial |
Completed |
NCT01556646 |
Phase 3 |
Tolvaptan |
40 |
Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy |
Completed |
NCT02173132 |
Phase 3 |
Acetyl-L-carnitine |
41 |
Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy |
Recruiting |
NCT04161053 |
Phase 3 |
Rifaximin;Nitazoxanide |
42 |
Evaluation of the Therapeutic Effect of Rifaximin on Covert Hepatic Encephalopathy With Underlying Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility in Liver Cirrhosis Patients |
Recruiting |
NCT04244877 |
Phase 3 |
Rifaximin |
43 |
The Potential Role of Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis: A Quadruple Blind Clinical Study |
Recruiting |
NCT05511766 |
Phase 2, Phase 3 |
Allopurinol 300 MG;Atorvastatin 20mg;Placebo |
44 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
Recruiting |
NCT05297448 |
Phase 3 |
Rifaximin SSD;Placebo |
45 |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis |
Recruiting |
NCT05071716 |
Phase 3 |
Rifaximin SSD;Placebo |
46 |
Shandong Provincial Integrated Traditional Chinese and Clinical Medicine(Chronic Hepatitis B and Its Complication) Prevention and Treatment Project |
Not yet recruiting |
NCT05128305 |
Phase 3 |
traditional Chinese medicine1 and traditional Chinese medicine 2 |
47 |
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial |
Terminated |
NCT00364689 |
Phase 3 |
Rifaximin;Lactulose |
48 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of MNK6105 (an Intravenous Formulation of L-Ornithine Phenylacetate) in Hospitalized Patients With Cirrhosis and Hyperammonemia Associated With an Episode of Hepatic Encephalopathy |
Withdrawn |
NCT04128462 |
Phase 3 |
MNK-6105;Placebo;Standard of Care |
49 |
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure |
Withdrawn |
NCT02086825 |
Phase 3 |
Rifaximin;Lactulose |
50 |
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy |
Unknown status |
NCT00281502 |
Phase 2 |
Rifaximin (drug) |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Kanamycin Sulfate
Lactulose
|
NEOMYCIN SO4 PWDR
|
|